Company
Clarus Therapeutics Holdings, Inc.
Headquarters: Northbrook, IL, United States
CEO: Dr. Robert E. Dudley Ph.D.
Clarus Therapeutics Holdings, Inc. Categories
United States Healthcare Drug Manufacturers—GeneralUnited States Healthcare United States Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
| Merck | $244.44 B |
| Roche | $219.35 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Clarus Therapeutics Holdings, Inc. has the following listings and related stock indices.
Stock: NASDAQ: CRXT wb_incandescent